• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by BioCryst Pharmaceuticals Inc.

    5/13/26 1:06:28 PM ET
    $BCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $BCRX alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001584348
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    BIOCRYST PHARMACEUTICALS INC
    SEC File Number
    000-23186
    Address of Issuer
    4505 EMPEROR BOULEVARD
    SUITE 200
    DURHAM
    NORTH CAROLINA
    27703
    Phone
    919-859-1302
    Name of Person for Whose Account the Securities are To Be Sold
    Barnes Alane P
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Fidelity Brokerage Services LLC
    900 Salem Street
    Smithfield � RI � 02917
    62500596250.0025416266005/13/2026
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common05/13/2026Option Granted - 12/20/2017IssuerCheckbox not checked6250005/13/2026Cash

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    Alane Barnes
    4505 Emperor Blvd.
    Suite 200
    Durham � NC � 27703
    Common03/16/20261500001372013.10

    144: Remarks and Signature

    Remarks
    Date of Notice
    05/13/2026
    Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1
    08/13/2025

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/Wade Moss, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Alane Barnes

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $BCRX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BCRX

    DatePrice TargetRatingAnalyst
    2/18/2026$17.00Outperform
    Evercore ISI
    10/15/2025$30.00Buy
    TD Cowen
    10/1/2025$8.00Outperform → In-line
    Evercore ISI
    4/29/2025$20.00Overweight
    Cantor Fitzgerald
    2/25/2025$15.00Outperform
    Wedbush
    11/20/2023$10.00Overweight
    JP Morgan
    9/18/2023$9.00 → $10.00Sector Perform → Outperform
    RBC Capital Mkts
    8/4/2023$11.00Hold → Buy
    Jefferies
    More analyst ratings

    $BCRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Evercore ISI resumed coverage on BioCryst Pharma with a new price target

    Evercore ISI resumed coverage of BioCryst Pharma with a rating of Outperform and set a new price target of $17.00

    2/18/26 8:21:17 AM ET
    $BCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    TD Cowen resumed coverage on BioCryst Pharma with a new price target

    TD Cowen resumed coverage of BioCryst Pharma with a rating of Buy and set a new price target of $30.00

    10/15/25 8:23:22 AM ET
    $BCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioCryst Pharma downgraded by Evercore ISI with a new price target

    Evercore ISI downgraded BioCryst Pharma from Outperform to In-line and set a new price target of $8.00

    10/1/25 8:12:55 AM ET
    $BCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Milne Jill C. was granted 1,262 shares, increasing direct ownership by 8% to 16,644 units (SEC Form 4)

    4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)

    6/2/26 4:16:22 PM ET
    $BCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Stonehouse Jon P was granted 631 shares, increasing direct ownership by 0.05% to 1,324,481 units (SEC Form 4)

    4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)

    6/2/26 4:14:06 PM ET
    $BCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Mckee Amy E was granted 631 shares, increasing direct ownership by 2% to 31,883 units (SEC Form 4)

    4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)

    6/2/26 4:11:14 PM ET
    $BCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting

    RESEARCH TRIANGLE PARK, N.C., May 27, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present seven abstracts from its hereditary angioedema (HAE) portfolio at the Annual Meeting of the European Academy of Allergy and Clinical Immunology (EAACI) taking place in Istanbul, Turkey, from June 12-15, 2026. Data include six abstracts featuring new clinical trial and real-world outcomes with ORLADEYO® (berotralstat), the first and only targeted oral prophylactic therapy for patients with HAE aged 2 and older, and one abstract featuring clinical trial outcomes with navenibart, a long-acting, monoclonal antibody plasma kallikrein inhib

    5/27/26 7:00:00 AM ET
    $BCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioCryst to Present New Real-World Evidence Underscoring the Ongoing Burden of Pediatric Hereditary Angioedema at ISPOR 2026

    RESEARCH TRIANGLE PARK, N.C., May 13, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present new real-world evidence at the 2026 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) conference taking place in Philadelphia from May 17–20, 2026. Studies highlight the significant healthcare and quality-of-life burden associated with hereditary angioedema (HAE) in pediatric patients and their caregivers, demonstrating persistent unmet needs and the importance of optimized disease management to reduce healthcare utilization. Underscoring the role of outcomes research in rare diseases, the research draws on large

    5/13/26 7:00:00 AM ET
    $BCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioCryst Reports First Quarter 2026 Financial Results and Provides Business Update

    — Q1 2026 ORLADEYO® net revenue of $148.3 million (+11% y-o-y; +21% y-o-y on comparable basis excluding European revenue) — — Announced licensing agreement for European commercial rights to navenibart for $70M upfront and milestone payments up to $275M — RESEARCH TRIANGLE PARK, N.C., May 06, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today reported financial results for the quarter ended March 31, 2026, and provided a business update. "We began 2026 with continued strong execution across our business, led by sustained growth of ORLADEYO and solid progress across our pipeline," said Charlie Gayer, President and Chief Executive Officer of BioCryst. "ORLADEYO con

    5/6/26 7:00:00 AM ET
    $BCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Levin Alan G bought $49,996 worth of shares (7,861 units at $6.36), increasing direct ownership by 21% to 44,951 units (SEC Form 4)

    4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)

    5/31/24 4:25:31 PM ET
    $BCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Aselage Steve bought $16,000 worth of shares (2,500 units at $6.40) (SEC Form 4)

    4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)

    5/29/24 4:16:35 PM ET
    $BCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Hutson Nancy J bought $31,900 worth of shares (5,000 units at $6.38), increasing direct ownership by 6% to 86,818 units (SEC Form 4)

    4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)

    5/22/24 7:24:51 AM ET
    $BCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCRX
    SEC Filings

    View All

    SEC Form 144 filed by BioCryst Pharmaceuticals Inc.

    144 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Subject)

    5/13/26 1:06:28 PM ET
    $BCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SCHEDULE 13G filed by BioCryst Pharmaceuticals Inc.

    SCHEDULE 13G - BIOCRYST PHARMACEUTICALS INC (0000882796) (Subject)

    5/12/26 9:59:36 AM ET
    $BCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by BioCryst Pharmaceuticals Inc.

    10-Q - BIOCRYST PHARMACEUTICALS INC (0000882796) (Filer)

    5/6/26 4:06:43 PM ET
    $BCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCRX
    Financials

    Live finance-specific insights

    View All

    BioCryst Reports First Quarter 2026 Financial Results and Provides Business Update

    — Q1 2026 ORLADEYO® net revenue of $148.3 million (+11% y-o-y; +21% y-o-y on comparable basis excluding European revenue) — — Announced licensing agreement for European commercial rights to navenibart for $70M upfront and milestone payments up to $275M — RESEARCH TRIANGLE PARK, N.C., May 06, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today reported financial results for the quarter ended March 31, 2026, and provided a business update. "We began 2026 with continued strong execution across our business, led by sustained growth of ORLADEYO and solid progress across our pipeline," said Charlie Gayer, President and Chief Executive Officer of BioCryst. "ORLADEYO con

    5/6/26 7:00:00 AM ET
    $BCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioCryst to Report First Quarter 2026 Financial Results on May 6

    RESEARCH TRIANGLE PARK, N.C. , April 15, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2026 financial results on Wednesday, May 6, 2026. BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update. The live call may be accessed by dialing 1-844-481-2942 for domestic callers and 1-412-317-1866 for international callers. A live webcast and replay of the call will be available online in the investors section of the company website at www.biocryst.com. About BioCryst Pharmaceuticals BioCryst is a global biotechnolo

    4/15/26 7:00:00 AM ET
    $BCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioCryst Reports Full Year 2025 Financial Results and Provides Business Update

    —Full year 2025 ORLADEYO® net revenue of $601.8 million (+38% y-o-y; +43% y-o-y excluding European ORLADEYO revenue following the sale of the European ORLADEYO business to Neopharmed Gentili S.p.A. on October 1, 2025)— —Record GAAP and non-GAAP operating profit for full year 2025— —Maintained full year 2026 ORLADEYO revenue guidance between $625 and $645 million— —Received FDA approval for ORLADEYO oral pellets for patients with HAE Aged 2 to <12 Years— —Completed Acquisition of Astria Therapeutics— RESEARCH TRIANGLE PARK, N.C., Feb. 26, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today reported financial results for the full year ended December 31, 2025, an

    2/26/26 7:00:00 AM ET
    $BCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCRX
    Leadership Updates

    Live Leadership Updates

    View All

    BioCryst Appoints Sandeep M. Menon Chief Research and Development Officer

    — Experienced R&D leader with a track record of advancing innovative therapies from early development to global approval —  RESEARCH TRIANGLE PARK, N.C., April 06, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced the appointment of Sandeep M. Menon, MD, PhD, as Chief Research and Development Officer. Building on the commercial success of ORLADEYO® and the recent acquisition of Astria Therapeutics and the navenibart program, BioCryst is entering a new phase of execution in its strategy to build value through development and commercialization of rare disease therapies. Dr. Menon joins BioCryst from Alnylam Pharmaceuticals, where he served as Chief Devel

    4/6/26 7:00:00 AM ET
    $BCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioCryst to Highlight Patient-focused Research at the 2025 US HAEA National Summit

    RESEARCH TRIANGLE PARK, N.C., July 09, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present new findings from patient-focused research highlighting the burden of current treatments for HAE on pediatric patients under the age of 12 and their caregivers and perspectives on the importance of HAE treatments. The findings will be presented in posters at the 2025 US HAEA National Summit in Baltimore, which is taking place July 10-13, 2025. "For more than a decade, we have been honored to join the HAE patient community at the US HAEA National Summit. It is an opportunity for us to hear directly from them on their hopes and dreams

    7/9/25 7:00:00 AM ET
    $BCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioCryst Appoints Babar Ghias Chief Financial Officer and Head of Corporate Development

    RESEARCH TRIANGLE PARK, N.C., July 07, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced the appointment of Babar Ghias as chief financial officer (CFO) and head of corporate development. Mr. Ghias joins BioCryst from AvenCell Therapeutics, a clinical-stage CAR-T company focused on hematologic malignancies, where he served as CFO since 2022. "Babar brings extensive deal making and operational experience in addition to his previous roles as a CFO at rare disease companies. The addition of these skills and expertise to the leadership team are exactly what we need at this time as we look to deploy capital and accelerate our path to sustainable growth and

    7/7/25 7:00:22 AM ET
    $BCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by BioCryst Pharmaceuticals Inc.

    SC 13G/A - BIOCRYST PHARMACEUTICALS INC (0000882796) (Subject)

    11/7/24 10:52:17 AM ET
    $BCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by BioCryst Pharmaceuticals Inc.

    SC 13G/A - BIOCRYST PHARMACEUTICALS INC (0000882796) (Subject)

    11/7/24 10:25:46 AM ET
    $BCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by BioCryst Pharmaceuticals Inc.

    SC 13G/A - BIOCRYST PHARMACEUTICALS INC (0000882796) (Subject)

    11/4/24 11:18:36 AM ET
    $BCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care